Monte Rosa Therapeutics Soars in Pre-Market Trading After Securing $5.7 Billion Licensing Deal with Novartis for Immune-Mediated Disease Therapies

Intelligene News APP learned that on Monday, Swiss pharmaceutical company Novartis (NVS.US) signed a licensing and collaboration agreement worth up to $5.7 billion with drug development company Monte Rosa Therapeutics (GLUE.US) to jointly develop drugs for immune-mediated diseases. Under the agreement, Monte Rosa will receive an upfront payment of $120 million and have the opportunity to earn additional payments through milestone payments and sales royalties, bringing the total potential value of the deal to $5.7 billion. Following the news, as of press time, Monte Rosa's stock surged over 53% in pre-market trading on Monday.

It is reported that immune-mediated diseases refer to the immune system mistakenly attacking healthy tissues, causing inflammation and damage. These difficult-to-treat diseases can seriously affect patients' quality of life. The agreement grants Novartis exclusive rights to an undisclosed drug discovery target and provides the option to license two additional research projects from Monte Rosa Therapeutics’ early immunology pipeline.

Monte Rosa Therapeutics will leverage its AI-driven platform to discover and develop new degraders—small molecule compounds specifically designed to break down disease-causing proteins—which will then be advanced into clinical development and commercialization by Novartis.

This collaboration marks the second partnership between the two companies. Last year, the parties reached an agreement on MRT-6160, which is currently in the early stages of clinical trials for the treatment of autoimmune and inflammatory diseases.

This agreement is also the second major deal reached by Novartis this month. Prior to this, Novartis had just signed a cooperation agreement worth up to $5.2 billion with Argo Biopharmaceutical for the development of an experimental heart disease drug.